Betamethasone

Betamethasone is a synthetic corticosteroid of the glucocorticoid class, chemically one of the methasone steroids. It is distinguished by a methyl group at the 16 position of the steroid skeleton, and it is a stereoisomer of the closely related drug dexamethasone, from which it differs only in the spatial arrangement of that group. Like other glucocorticoids, it is a highly potent, long-acting anti-inflammatory and immunosuppressive agent.

The drug is used across many fields of medicine. In dermatology it treats inflammatory skin conditions such as eczema, psoriasis, and dermatitis; in rheumatology and immunology it is given for disorders including rheumatoid arthritis and systemic lupus erythematosus; and it is also used in allergic and respiratory conditions and in certain cancers ^[1]. Among its most important obstetric uses is administration to women at risk of preterm delivery, where a course given before birth accelerates maturation of the fetal lungs and reduces the complications of prematurity ^[1]. It has also been examined in more specialized settings, such as a trial of oral betamethasone that reduced movement symptoms in children with the rare disorder ataxia telangiectasia ^[3], and as a topical treatment that helps resolve phimosis in boys, offering a non-surgical alternative in many cases ^[4].

The use of corticosteroids to prepare premature lungs traces back to experiments by Liggins in fetal sheep in the late 1960s, which unexpectedly showed lung inflation in very premature lambs, followed by the first human randomized trial by Liggins and Howie in 1972 ^[2]. Decades of subsequent trials, summarized in Cochrane systematic reviews, established that a single course of antenatal corticosteroids such as betamethasone lowers the risk of newborn death, respiratory distress syndrome, and bleeding within the brain, an effect that holds across high, middle, and low resource settings ^[1]. This body of evidence underlies the routine use of the drug in threatened preterm birth ^[1].

Because it acts on the body's stress-hormone system, betamethasone produces wide-ranging effects and is supplied in many forms to suit different targets, including oral tablets, intramuscular and local injections, and topical creams, lotions, gels, foams, and sprays. Injected preparations begin to reduce inflammation within a few hours and can act for several days. As with all systemic glucocorticoids, prolonged or high use carries a well-recognized set of risks, so treatment is generally kept to the lowest effective course.

Betamethasone was patented in 1958 and came into medical use in the early 1960s. It is included on the World Health Organization's Model List of Essential Medicines, reflecting its importance in basic health systems, and it is available as an inexpensive generic in most countries. It remains among the more commonly prescribed medications, particularly in its topical and injectable forms.

Betamethasone is a prescription steroid. Short courses can raise blood sugar, disturb sleep and mood, boost appetite, and cause mild fluid retention or stomach upset. Repeated or prolonged use carries bigger risks; adrenal gland suppression, bone thinning, weight gain and a rounded face, skin thinning, cataracts, muscle weakness, slowed wound healing, and greater susceptibility to infection. Depot injections can cause local skin or fat shrinkage and temporary flushing. It should not be stopped abruptly after a long course because the adrenal glands need time to recover, and it is avoided in untreated systemic infections; live vaccines are generally not given during treatment.

Betamethasone is a systemic corticosteroid cleared largely by CYP3A4, so enzyme inducers and inhibitors move its exposure in both directions. Rifampin, phenytoin, carbamazepine and phenobarbital cut steroid levels and can let the underlying disease flare; strong inhibitors such as ritonavir, itraconazole and clarithromycin push exposure up and bring Cushingoid features and adrenal suppression with them.

The pharmacodynamic interactions matter more day to day. NSAIDs and corticosteroids together raise the risk of gastrointestinal ulceration and bleeding well above either alone. Potassium-wasting diuretics and amphotericin B compound the steroid's own potassium loss, which becomes a rhythm problem in anyone taking digoxin. Warfarin control tends to become unpredictable in either direction, so INR is watched more closely around any change in steroid dose.

Live attenuated vaccines are the hard limit: at immunosuppressive doses the vaccine response is blunted and disseminated vaccine infection becomes possible.

Checking a whole stack? Run it through interactions + stacks.

Betamethasone was developed in the late 1950s as part of a wave of fluorinated corticosteroids created to improve on hydrocortisone; it is the 16-beta-methyl stereoisomer of dexamethasone and entered clinical use in the early 1960s. Its most influential application arose from the work of Graham Liggins and Ross Howie in New Zealand, who observed in sheep experiments that fetal glucocorticoid exposure accelerated lung maturation and then confirmed in a 1972 controlled trial that betamethasone given to mothers reduced neonatal respiratory distress. That finding transformed the care of anticipated premature birth and remains one of the foundational discoveries of modern perinatal medicine. Betamethasone is now available worldwide as a generic in tablet, injectable, and topical forms, and it appears on the World Health Organization's List of Essential Medicines.

Betamethasone is regarded as a durable, high-value medicine; the antenatal corticosteroid course it helped establish is considered among the most cost-effective interventions in obstetric care, reducing perinatal and neonatal death as well as respiratory distress. As a potent, long-acting glucocorticoid it is valued in dermatology, rheumatology, and allergy for reliable anti-inflammatory control, and its depot injectable forms offer prolonged local action. Clinicians respect it while remaining mindful of the well-known trade-offs of systemic corticosteroids, including metabolic and immunosuppressive effects with extended use. Its longevity on essential-medicine lists reflects a strong, evidence-backed track record.